Percutaneous nephrolithotomy (PCNL) is the gold standard treatment for large renal and ureteric stones. A nephrostomy tube is often inserted post-operatively to reduce complications such as tract haemorrhage and infection. However, nephrostomy tubes cause significant discomfort, increasing both analgesic requirements and length of inpatient stay. Whilst tubeless PCNL has been shown to be safe in low-risk patients, the risk of above complications remains. To address these concerns, clinicians have trialled applying haemostatic agents (HA) to the tract, with varied results. We aim to determine if HA are safe and clinically beneficial in PCNL. Systematic review of literature yielded 97 original research articles. Seventeen papers were deemed suitable after abstract screening and eligibility criteria application. These 17 research studies compared either tubeless PCNL vs PCNL with HA or PCNL with nephrostomy tube vs PCNL with HA. Within these studies a wide range of HA with differing mechanisms were used. Outcomes compared, where available, included bleeding (as determined by Hb drop or transfusion rates), pain scores, analgesic requirements, length of hospital stay and complication rates. We conclude that low-risk patients undergoing tubeless PCNL are unlikely to benefit from HA. However, potential remains in using HA to complement or replace nephrostomy tube in patients with significant intraoperative bleeding. Further studies are required to determine the optimal patient demographic who may benefit from HA, with a focus on cost-benefit analysis. Whilst HA were found to be safe, concerns remain regarding inadvertent collecting system injection and long-term effects, as well as increased cost.
Introduction
Percutaneous nephrolithotomy (PCNL) is the gold standard treatment for large upper ureteral or renal stones. Fernstrom and Johannson are credited with being the first team to treat renal stones percutaneously [1] . Significant modifications have been made since. One key addition was the insertion of a nephrostomy tube to the access tract. This is done with the belief that it reduces complications such as tract haemorrhage and infection and enables second-look PCNL if required [2] . However, recent studies have shown tubeless PCNL to be safe and effective in select patient groups [3] . Tubeless procedures result in less postoperative discomfort and lower post-operative analgesia and therefore lead to earlier discharge from hospital [2] .
However, the risk of above-mentioned complications remains, preventing tubeless PCNL being adopted as standard. To mitigate these concerns, numerous haemostatic agents (HA) have been applied to the PCNL access tract. The benefit of these, in theory, is reduced tract haemorrhage. The limitations to their use are cost, uncertain effectiveness and potential side effects. Naturally, well-constructed randomised control trials are needed to assess their use.
Whilst numerous studies investigating HA have been conducted, they are of varying quality and often investigate different HA with varying mechanisms of action. In this article, we provide a comprehensive literature review surrounding This article is part of the Topical Collection on Surgery Electronic supplementary material The online version of this article (https://doi.org/10.1007/s42399-019-00194-y) contains supplementary material, which is available to authorized users.
Results
As mentioned above, all studies discussed below underwent quality assessment. In our review, seven of nine RCTs scored ≥ 3, which indicates a high-quality study [4] (see Table 1 for details).
Six of eight non-RCTs in our review scored 6/9 on the Newcastle-Ottawa scoring system [5] . The remaining two non-RCTs scored 5/9. There is no universal consensus on what constitutes a high-quality score (see Table 2 for details).
Tubeless PCNL vs Haemostatic Agents
As mentioned earlier, tubeless procedures are considered safe and effective in low-risk patients. Generally, this constitutes patients with minimal intraoperative bleeding, no need for second-look procedure and an intact collecting system [3] . Multiple studies have focused on using HA in this patient subset to further minimise an already low complication rate.
In 2006 Shah et al. carried out tubeless PCNL on 17 consecutive low-risk patients with the injection of 2 ml of fibrin glue (Tisseel) into the access tract [6] . Various data points were collected post-operatively including haemoglobin (Hb) drop, analgesic requirements and mean length of inpatient stay. This was compared to data collected retrospectively from 25 consecutive low-risk patients who had undergone tubeless PCNL without HA the year before. No major complications, including urinoma or haematoma formation, occurred in either group. One patient in each group required a blood transfusion. Patients receiving fibrin were found to undergo a lower Hb drop post-operatively (control = 1.43 g/dl vs experimental = 1.18 g/ dl), but this was not statistically significant. Patients receiving fibrin required significantly less analgesia post-operatively (control = 159 mg diclofenac vs experimental = 114.71 mg diclofenac). This led to patients in the experimental group being discharged on average 7 h earlier, although this was not found to be statistically significant. Surprisingly, the difference in analgesic requirements did not translate into a significant difference in post-operative pain score (control = 5.28 vs experimental = 4.23), as measured by visual analogue scale (VAS). Whilst this small sample study found fibrin glue to be safe, minimal clinical benefit was derived from its use. Tisseel was expensive (225$ per 2 mls) which would make its routine use difficult in the current health systems' financial constraints.
Subsequently, Shah et al. carried out a prospective randomised control trial comparing tubeless PCNL to PCNL with fibrin sealant injection (Tisseel) [7] . About 63 patients undergoing PCNL were randomised to receive either tubeless PCNL or installation of fibrin into the access tract. Once again, only low-risk patients suitable for tubeless PCNL were selected. Patients receiving fibrin were found to have significantly lower VAS pain scores on post-operative days 1, 2 and 3. No significant difference was found between groups in Hb decrease. Patients receiving fibrin had a shorter post-operative stay (experimental = 32.65 h vs control = 37.22 h), although this was not found to be significant. Two patients in each group required a blood transfusion. One patient receiving fibrin suffered a considerable reduction in Hb post-operatively (6 mg/dl) due to haematoma formation. This same patient developed sepsis and required admission to the intensive care unit for 4 days.
Aghamir et al. [8] were one of the first to test Surgicel gauze as a HA. They conducted a prospective pilot study comparing totally tubeless PCNL with and without application of HA post-operatively. About 20 patients enrolled and 10 were randomised to each group respectively. Those in the experimental group received Surgicel application to their access tract post-operatively. The outcomes measured were postoperative haematocrit drop (4.1 g/dl in control group vs 2.5 g/ dl in Surgicel group respectively) and urinary extravasation (two patients in each group). No significant difference was found in these outcomes between groups. No information was given regarding complications. Table 2 Newcastle-Ottawa scoring system for non-RCTs [5] Shah et al. [4] Sepulveda et al. [14] Nagele et al. [15] Koo et al. [16] Dah-Shyong Yu [17] Lan et al. [18] Kim et al. [19] Auciello et al. [20] 
Selection
Representativeness of the exposed cohort
Selection of the non- Total score 6/9 6/9 5/9 6/9 5/9 6/9 6/9 6/9 * 1 point, high-quality choice (maximum 1 point counts towards final score in each subsection of "Selection" and "Outcome") d No description of derivation of cohort c No description of derivation of non-exposed cohort -No point scored Ziaee et al. [7] Istanbulloglu et al. [8] Singh et al. [9] L et al. [10] He et al. [11] Cormio et al. [12] Kumar et al. [13] Described as randomised Studies with a score of 3 ≤ are considered high quality A randomised control trial by Ziaee et al. [9] in 2013 investigated the use of autologous fibrin sealant in tubeless PCNL. About 43 patients were randomised to a control group (tubeless PCNL) and an experimental group (tubeless PCNL with fibrin sealant). No significant difference was found between the two groups in mean Hb post-operatively, transfusion rates (none in both groups), residual stones or mean hospitalisation time. Interestingly, this study applied the patient's own blood to prepare the fibrin glue. The authors advocated that this can mitigate concerns regarding blood borne diseases and anaphylaxis. However, given the extra work this involves and the rare nature of the above complications, it is debatable whether this is ultimately beneficial.
Istanbulluoglu et al. [14] carried out a prospective randomised control trial in 2013. They randomised 90 patients into 2 groups. The control group received tubeless PCNL. The experimental group received compression of the access tract with a sponge soaked in Ankaferd Blood Stopper (ABS) for 2 min. All patients were low risk, meaning no evidence of severe persistent haemorrhage, intact collecting system, no need for second-look procedure and single access tract. They detected a significant difference in Hb drop post-operatively favouring the ABS group (experimental = 1.40 mg/dl vs control = 1.84 mg/dl). In keeping with this, they also found time to cessation of haematuria to be significantly lower in the experimental group (experimental = 9.60 h vs control = 11.95 h). No significant difference was found in operative time, VAS score, length of hospitalisation and complication rates between the two groups. One patient in the experimental group required angioembolisation for a pseudoaneurysm.
Singh et al. carried out a prospective randomised control trial of 50 patients investigating the use of absorbable haemostatic gelatin sponge (Spongostan) in patients undergoing tubeless PCNL [19] . Like previous studies investigating tubeless PCNL, the patients selected were of low risk. No significant difference was found between the two groups in post-operative Hb drop. No patients in either group required a blood transfusion or suffered major post-operative complications. Surprisingly, the experimental group recorded significantly lower VAS pain scores (experimental = 4.60 vs control =6.03). It is likely that this lower pain score led to significantly lower analgesic requirements (experimental = 300-mg diclofenac vs control =416.67-mg diclofenac), shorter hospitalisation period (experimental = 1.99 days vs control = 2.15 days) and significantly shorter time to return to work (experimental = 4.3 days vs control = 7.2 days). However, the mean stone burden preoperatively was also significantly greater in the control group (control 736.67 mm2 vs experimental 500 mm2). This could substantially affect the patients' perceived level of pain, thereby introducing bias to the results.
Sepulveda et al. conducted a retrospective analysis of 52 patients undergoing tubeless PCNL by the same surgeon [20] . The first 25 patients received standard tubeless PCNL with no addition of HA, whilst the following 27 patients were subjected to application of a cylinder of Surgicel and a 1 unit of Gelita into the access tract. No significant difference between groups was found in haematocrit change, post-operative VAS pain scores, time to discharge and operative time. All patients underwent a non-contrast CT scan on post-operative day 1. One patient in the control group was found to have a haematoma, compared to two patients in the experimental group. All three patients were treated conservatively, and their haematomas showed complete resolution on non-contrast CT performed 3 months post-operatively. No urinomas were reported.
Kim et al. [15] were the first to compare outcomes between major haemostatic agents. They conducted a retrospective analysis of 158 patients who underwent totally tubeless PCNL by a single surgeon. About 107 patients received fibrin sealant (Tisseel), and 51 patients received gelatin matrix (Floseal). To reduce bias, 2:1 propensity score matching was applied. This matched 98 fibrin sealant patients to 49 gelatin matrix patients. All patients received a CT scan on postoperative day 1. No significant difference was found in urinoma or haematoma formation, haemoglobin change, angioembolisation rates stone free rates, time to discharge and post-operative VAS score. However, a significantly greater number of patients receiving gelatin matrix required postoperative ureteral stent placement (fibrin sealant = three patients vs gelatin matrix = eight patients).
Auciello et al. [16] conducted a retrospective analysis comparing 294 patients who underwent tubeless mini-PCNL to 197 patients who underwent standard PCNL with application of TachoSil sealant. Surprisingly a significantly greater Hb drop was seen in patients receiving PCNL with sealant (sealant = 1 vs tubeless = 0.8). However, this did not result in a significantly different number of blood transfusions between groups. No significant difference was found between embolization rates, stone free rates, urinary leakage, infective complications or length of hospital stay.
Nephrostomy Tube vs Haemostatic Agent
Nagele et al. were the first group to use a gelatin matrix haemostatic sealant (Floseal) in the percutaneous access tract in an attempt to replace nephrostomy tube placement post-PCNL [17] . The authors conducted a retrospective note review of 11 consecutive patients undergoing mini-PCNL with Floseal in the tract post-operatively versus 11 consecutive mini-PCNL cases receiving the standard nephrostomy. The first five patients did undergo intravenous urogram to ensure an intact collecting system, but this was omitted for the remaining patients. Unfortunately, no statistical analysis was carried out in this study. However, at face value, there was lower analgesic requirements in the experimental group (control = paracetamol for 2.8 days + opioids for 0.5 days vs experimental = paracetamol for 0.5 days alone, respectively). Patients receiving Floseal also required less time in hospital (control = 2.5 days vs experimental = 3.4 days). No substantial difference in post-operative Hb decrease was detected (experimental = 1.6 g/dl vs control = 1.7 g/dl). One patient in each group suffered urinary extravasation. Two patients receiving Floseal developed pyrexia post-operatively with no signs of sepsis. In one patient, the Floseal syringe became misplaced before application, resulting in injection of Floseal into the collecting system. This resulted in urinary extravasation, although there is no data regarding long term effects.
Koo et al. conducted a retrospective case note study of 92 patients with significant parenchymal bleeding (defined as unclear visualisation of intrarenal structures at full irrigation of nephroscope) [13] . About 52 patients received a standard nephrostomy tube. And 40 patients received only compression of the parenchymal tract using QuikClot for 5 min. QuikClot is a Surgicel gauze impregnated with Kaolin. Kaolin activates factor 12, the first factor in the intrinsic pathway of coagulation cascade. The unit cost for QuikClot in this study was 43$. Only one patient needed conversion to nephrostomy tube after QuikClot application. This patient was excluded from analysis. No significant difference was found in mean post-operative Hb reduction. Patients receiving QuikClot recorded significantly lower VAS pain scores on post-operative days 0, 1 and 2. This likely led to the lower analgesic requirements (experimental = 230.5-mg tramadol vs control = 294.5-mg tramadol) and shorter inpatient stay (2.52 days vs 3.39 days), both of which were statistically significant. No major complications occurred in either group. Minor complication rates were comparable for both groups. Four patients receiving QuikClot suffered delayed haematuria vs two patients who received nephrostomy tube. One patient receiving nephrostomy tube required return to hospital due to flank pain, and one further patient in this group suffered fever > 38°C. No patients in the QuikClot group suffered these complications.
Yu Dah-Shyong carried out a prospective study investigating the use of absorbable haemostatic gelatin foam sponge (Gelfoam) in PCNL [10] . About 15 patients undergoing PCNL received a nephrostomy tube, whilst 15 patients received tubeless PCNL with application of Gelfoam to the access tract. No information is given which would allow us to risk stratify patients, such as level of intraoperative bleeding or pelvicalyceal system injury. Whilst no information is given regarding changes in Hb, the experimental group required significantly fewer blood transfusions (experimental = 1 vs control = 4). No data was collected regarding patients experience of post-operative pain, such as VAS scores. However, patients who received Gelfoam did require significantly less analgesia (control = 185-mg demerol vs experimental = 85mg demerol). Patients receiving Gelfoam were also discharged significantly earlier (experimental = 3.4 days vs control = 5.1 days). No major complications were reported in either group. Interestingly, all patients receiving Gelfoam also underwent insertion of a retroperitoneal drainage tube. It is possible that this introduced bias to the results and further investigation into its use would be prudent.
Kumar et al. [11] conducted a prospective randomised control trial of 113 patients comparing nephrostomy tube insertion to a novel haemostatic seal they named "Santosh-PGI haemostatic seal". This seal consists of a strip of Surgicel wrapped around a gelatin sponge (Gelspon). This is soaked in a solution of 250-mg tranexamic acid with 5 ml of 1:1000 noradrenaline. Patients receiving the haemostatic seal suffered significantly less post-operative pain (haemostatic group = 3.79 vs control = 6.12) required significantly less postoperative analgesia and had a significantly shortened length of stay (haemostatic group = 0.48 days vs control = 4.74 days). Patients in the haemostatic group also suffered fewer complications (haemostatic group 19.6% vs control 47.7%). Patients receiving haemostatic sealant suffered significantly lower Hb drop (haemostatic group = 1.05 g/dl vs control = 1.3 g/dl) and lower incidence of urine leakage (haemostatic group = 3.6% vs control = 21.1%). Patients in the haemostatic sealant group also returned to normal activities significantly faster (haemostatic group = 8.05 days vs control 18.42 days). Four patients in the haemostatic group required readmission. Three of these were for tract site abscess, with one needing a DJ stent. The remaining patient was readmitted with haematuria which resolved with conservative management. In comparison, only one patient with nephrostomy tube required readmission. However, this difference was not found to be statistically significant.
Li et al. carried out a prospective randomised trial comparing three different methods of PCNL tract closure [18] . Thirtyone patients were randomised to receive either only a fascial stitch (tubeless PCNL), cope loop nephrostomy tube or application of Floseal (gelatin-thrombin haemostatic matrix) into the access tract. No significant difference was detected in estimated blood loss, change in Hb, analgesic requirement or length of hospitalisation. Surprisingly, the mean VAS pain score 1 week post-operatively was higher in the group receiving Floseal (Floseal = 25.1, fascial stitch = 15.6, cope loop = 4.6). VAS scores were collected preoperatively, immediately post-operatively, 1 week post-operatively, 1 month postoperatively and 3 months post-operatively. Analysis of these time points shows mean VAS score rise post-operatively for 1 week, before falling. As Floseal expands in size and provides mechanical tamponade and is absorbed over a few weeks, it is feasible that Floseal continues to cause pain until its resorption reaches a certain stage. On the other hand, nephrostomy tubes were removed prior to discharge, at which point the level of pain should subside noticeably. Interestingly, this study also included a quality of life questionnaire, conducted at the same time points as the VAS scoring. This showed no significant difference between groups. This is arguably a better indicator of patient experience than VAS pain score alone. Complication rates were comparable between groups. One patient from both cope loop and fascial stitch group developed post-op low-grade pyrexia. One patient in the Floseal group had a flare of their MS. A second-look procedure was performed in one patient receiving nephrostomy tube and two patients receiving fascial stitch due to residual stones being found on post-op non-contrast CT. One fascial stitch patient receiving fascial stitch who underwent second-look procedure represented 2 days later with signs of pyelonephritis and required antibiotics, ureteral stent change and renal pelvis washout.
He et al. carried out a prospective randomised control trial comparing PCNLs carried out by a single surgeon [12] . The control group received a standard nephrostomy tube placement, whilst experimental group received placement of a modified nephrostomy; the tube was covered in absorbable haemostatic gauze. This is the first study to use such a modification to a nephrostomy tube. About 91 patients received a standard nephrostomy tube, whilst 97 patients received a modified nephrostomy tube. Post-operative blood loss was significantly lower in the group receiving modified nephrostomy tube (control = 25.76 g/dl vs experimental = 14.25 g/dl). Fewer patients receiving modified nephrostomy tube required blood transfusions (control = 5 vs experimental = 1) and selective renal artery embolisation for bleeding (control = 4 vs experimental = 1). However, these differences were not found to be significant. The length of hospitalisation was similar between the two groups. No data was given regarding pain scores and analgesic requirements. However, given that both groups received a nephrostomy tube, this is unlikely to have been different. The absorbable gauze (ETHICON) is absorbed in 7-14 days. The mean follow-up period was roughly 10 months. During this time, no complications related to the absorbable gauze were reported.
Lan et al. [21] conducted a retrospective review of 139 PCNL procedures, comparing nephrostomy tube insertion (82 patients) vs tubeless PCNL (41 patients) with gelatin matrix haemostatic sealant (Floseal). To mitigate concerns regarding intracortical sealant injection, they used a balloon occlusion technique. Whilst usually patients are offered tubeless PCNL based on their risk factors (intact collecting system, low risk of intraoperative bleeding and no need for second-look procedure), patients in this study could choose which treatment to receive after discussion of risk and benefits. No significant difference was found between groups in postoperative complications, stone free rates or operative time. Patients receiving tubeless PCNL with HA application spent significantly less time as an inpatient (2 days vs 3 days) and scored significantly less on visual analogue pain scale (2 vs 3). Unsurprisingly, a significantly lower proportion of patients in the tubeless group required opioids as compared to those receiving a nephrostomy tube (17.1% vs 39%). The Hb drop was lower in those receiving nephrostomy tube, but this difference was not found to be significant (1.15 g/dl vs 1.6 g/dl. respectively). Conversely, fewer patients receiving tubeless PCNL with HA application required a blood transfusion (1 vs 12), but again this was not found to be significant.
Cormio et al. [22] conducted a randomised control trial of 100 patients comparing nephrostomy tube insertion (control group) to tubeless PCNL with TachoSil application (experimental group). TachoSil is a collagen sponge coated in thrombin and fibrinogen. The primary comparators were bleeding and urinary leakage. Other data collected included pain, analgesic requirements and length of hospital stay. Ultrasound was performed every 12 h until discharge to detect perirenal bleeding or urinary extravasation. No significant difference was found in post-operative Hb decrease, perirenal haematoma formation, mean analgesic requirements or mean VAS pain score on day 1. However, significantly fewer patients in the experimental group developed urinary leakage (control = 9% vs experimental = 1%). Furthermore, patients receiving the experimental treatment required significantly shorter length hospital stays (control = 5.15 days vs experimental = 2.75 days). One patient in the experimental group and three in the control group were excluded from analysis as they developed hydrothorax and "relevant bleeding" respectively. Whilst this study suggests TachoSil use reduces inpatient stay by an average of 3 days and reduces urinary leakage, this benefit must be balanced against the high cost of TachoSil; each unit costs roughly £300. Table 3 and Table 4 provide a summary of the baseline characteristics of the studies discussed, whilst Table 5 and Table 6 provide a summary of the major outcomes.
Discussion
Nephrostomy tube is the principal cause of post-PCNL morbidity, causing much of post-operative pain, leading to increased analgesic requirements and lengthening inpatient stay. When the concept of tubeless PCNL was first conceived, urologists were initially concerned that absence of a nephrostomy tube would increase post-operative complications such as haematomas and urinomas. However, subsequent research has found tubeless PCNL to be safe in selected, low-risk patients, that is, patients with low levels of intraoperative bleeding, no injury to the collecting system and no need for secondlook PCNL. The removal of nephrostomy tube and its associated morbidity leads to less post-operative pain, analgesic requirements and shorter lengths of inpatient admission.
This leads us to consider the role of HA in PCNL. As discussed above, tubeless PCNL is carried out in selected, low-risk patients in whom the risk of bleeding is already minimal. Recent PCNL studies have shown post-operative blood transfusion rates as low as 0.8% [3] . This suggests HA are unlikely to produce significant benefit in this patient profile. This theory is supported by our review in which no study comparing tubeless PCNL with tubeless PCNL plus HA revealed a significant difference in major post-operative complications, such as urinoma or haematoma formation. Similarly, a meta-analysis by Yu C et al. in 2014 showed no difference in complication rate when comparing tubeless PCNL to HA use [23] . Therefore, it is worth considering that tubeless PCNL in low-risk patients results in minimal complications and this Perhaps the real question is whether HA would benefit high-risk patients with significant bleeding in whom nephrostomy tubes would classically be used. Just as certain groups are considered low risk, certain patient populations could be considered at higher risk of complications following tubeless PCNL. Aucellio et al. [16] hypothesised that elderly patients (> 70 years) may benefit from haemostatic agents as they would be expected to have a less efficient healing process. However, there was no significant difference in complications when comparing tubeless mini-PCNL vs PCNL with TachoSil application in those over 70 years old. These findings should be viewed with caution as mini-PCNL requires smaller puncture size which could reduce the development of post-PCNL complications. Furthermore, when comparing transfusion rates within the tubeless group, elderly patients (> 70 years) were found to require twice as many transfusions as their younger counterparts (> 70 years = 7.1% vs < 70 years = 3.1%). This difference was not statistically significant. These findings do warrant further investigation using high-quality randomised controlled trials. Certain studies have shown possible benefit from HA. Istanbulluoglu et al. did show significantly faster resolution of haematuria and significantly lower post-operative Hb drop when using ABS as HA. However, this did not translate into a significant difference in need for blood transfusion, nor in time to discharge. It could therefore be argued that these findings had little clinical significance [14] . Singh et al. showed a significantly shorter time of urine leakage when using Spongostan and smaller average size of urinoma [19] . However, the control group in this study has a significantly greater stone burden (control = 736.67 mm2 vs experimental = 500 mm2) which may introduce bias. Furthermore, whilst data on mean urinoma size has been collected, no information is given regarding number of patients with clinically significant urinoma. Patient enrolment numbers in both above studies were relatively low, increasing the risk of type 2 error. Nevertheless, these findings warrant further prospective randomised control trials to see if patients stand to benefit from the use of HA in tubeless PCNL.
Nephrostomy tube insertion post-PCNL is still widely considered as the safest option in patients with significant intraoperative bleeding. An ideal HA would be equally safe to use in these patients whilst causing significantly less postoperative discomfort. The use of QuikClot by Koo et al. is one of the most promising studies so far. They found QuikClot significantly reduced post-operative pain, analgesic requirement and length of inpatient stay whilst causing no significant increase in post-operative complications such as haematomas and urinomas. This results in a better patient experience, lower chance of hospital acquired infection as a result of shorter stay and likely an improved cost-benefit ratio [13] . Yu Da-Shyong showed similar results whilst comparing Gelfoam to nephrostomy tubes. Their study showed significantly less post-operative analgesic requirements, quicker time to discharge and lower need for blood transfusions [10] . However, the lack of information regarding patient selection in this study, such as presence/absence of intraoperative bleeding, makes it difficult to put these findings into context. Furthermore, all patients receiving Gelfoam also received a retroperitoneal drain which adds another confounding factor.
Data from all the studies included in this review points towards HA generally being safe. No study reported a significant increase in post-operative complications when using HA, although further large sample and high-quality studies are needed to confirm this. However, there have been several non-human studies showing cause for concern. Uribe et al. [24] performed an in-vitro study showing that fibrin immediately forms a solid clot when in contact when urine. After 5 days, this clot remains as a thick mucus gel. A subsequent in vivo study using a porcine model by Kim et al. [25] found that 50% of kidneys injected with Tisseel (fibrin sealant) and Floseal (gelatin-thrombin matrix) were obstructed. A further porcine model study by Lipkin et al. [26] showed fibrin sealant persisting in the kidney for up to 30 days and possibly impairing wound healing. In our review, Nagele et al. mistakenly injected Floseal (gelatin-thrombin matrix) into the collecting system, resulting in urinary extravasation [17] . No long-term follow-up information is given. Although general consensus from the above studies is that gelatin-thrombin matrix preparations are safer than fibrin sealants, this highlights the real possibility of collecting system injection. Whilst further in vivo studies are conducted, we advise using caution. Retrograde balloon occlusion of the collecting system prior to injection of HA, as done by Borin et al. [27] and Lan et al. [21] , would minimise any potential risk.
Given the varying mechanisms of action of HA, we should also expect variation in their efficacy. The vast quantity of HA available makes the task of finding an optimal agent for use in PCNL a difficult one. The mechanism of HA can be thought of Thrombin and fibrinogen combine leading to clot formation as a spectrum. At one end, we have agents such as Tisseel (fibrin sealants). Tisseel is a combination of thrombin and fibrinogen, which is mixed at the site of injection [28] . This allows for clot formation independent of clotting factors from the patient. At the other end of the spectrum are gelatin products, such as Spongostan and Gelfoam. These provide a matrix for platelet aggregation, absorb blood and increase exponentially in size creating a tamponade effect. These products depend on the patient's intrinsic clotting factors to produce a clot. In the middle of the HA spectrum, we have gelatin-thrombin HA such as Floseal which also contain thrombin to aid the conversion of fibrinogen into fibrin to aid clot formation. Taking these mechanisms into account, it is possible that fibrin sealants are best used in low-risk cases suitable for tubeless PCNL where patients are unlikely to be actively bleeding significantly (thereby not providing a substantial source of their own clotting factors). By the same principle, gelatin-thrombin matrix products may be best suited to cases with active, significant bleeding. Table 7 provides a summary of HA covered in this review. Kumar et al. [11] combined Surgicel, a gelatin sponge (Gelspon), tranexamic acid and noradrenaline to create a novel haemostatic sponge. Combining agents with differing mechanisms of action may increase the ability of sealants to achieve haemostasis and prevent complications. This may partly explain the promising results of this study; patients receiving their novel haemostatic sealant required significantly less time in hospital, less post-operative analgesia, shorter time to return to normal activity, smaller Hb drop and less urine leakage through access tract.
The mechanisms of HA may also predispose each HA to specific complications. Kim et al. [15] demonstrated that patients receiving gelatin matrix (Floseal) are more likely to require ureteric stenting post-operatively as compared to patients receiving fibrin sealant (Tisseel). They hypothesised that this could be because gelatin matrix expands by 19-400% on contact with water. This leads to compression of the surrounding area. Inadvertent collecting system injection, as discussed above, may lead to ureteric obstruction and require ureteric stenting.
An interesting direction for future use of HA is synergistically with a nephrostomy tube, as done by He et al. [12] . In this study, the authors found that addition of haemostatic gauze to the nephrostomy tube significantly reduced post-operative bleeding and led to a smaller drop in Hb. Addition of the gauze also led to fewer patients needing a blood transfusion and super-selective renal artery embolisation, although this was not found to be statistically significant. This technique could potentially be beneficial for patients with significant levels of intraoperative bleeding by complementing the nephrostomy tube, rather than trying to replace it.
Conclusion
Given the growing body of evidence showing tubeless PCNL is safe in low-risk patients, the use of HA in this patient demographic may be unnecessary. This theory is supported by the findings of our review. However, potential remains for the use of HA in patients with significant intraoperative bleeding. This may involve HA replacing or complementing nephrostomy tube insertion. Whilst there are concerns regarding the safety of HA in non-human models, no major concerns were identified by the studies in this review. We recommend further large sample, prospective and high-quality studies to investigate the above issues. These studies should attempt to match HA by mechanism to appropriate patient subsets and have an added focus on cost-benefit analysis.
